Differential diagnosis of hypertension with electrolyte abnormalities

When a young patient presents with hypertension and hypokalaemia, it is important to consider secondary causes of hypertension, such as Conn’s syndrome (primary hyperaldosteronism), which can explain both findings. Coarctation of the aorta is another secondary cause of hypertension, but it does not account for the electrolyte abnormalities. Cushing’s disease/syndrome may also present with hypertension and electrolyte abnormalities, but typically with additional symptoms and higher fasting glucose levels. Polycystic kidney disease can cause hypertension, but not the electrolyte abnormalities. Primary (essential) hypertension is the most common form of hypertension, but secondary causes should be ruled out, especially in younger patients with atypical features.

Managing Foul Odors in Palliative Care

In palliative care, patients with fungating tumors may experience unpleasant smells caused by anaerobic organisms. Metronidazole is a medication that can help improve these odors by targeting the infecting organisms. Additionally, charcoal dressings can be used to absorb malodorous substances and provide some relief to patients.

It is important for healthcare professionals to be familiar with prescribing in palliative care. The British National Formulary (BNF) offers a helpful section on this topic, including introductory information that is often tested in exams. By utilizing these resources and strategies, healthcare providers can effectively manage foul odors and improve the quality of life for their patients in palliative care.

Amiodarone’s high iodine content (Am-IOD-arone) and direct toxic effect on the thyroid can lead to thyroid dysfunction, which may manifest as hypo- or hyperthyroidism. The patient’s symptoms are consistent with hypothyroidism, a known complication of amiodarone use. Each 200mg tablet of amiodarone releases approximately 6mg of free iodine, significantly exceeding the UK recommended daily allowance of 0.15 mg and increasing the thyroid’s iodine load. None of the other options listed are associated with hypothyroidism.

Amiodarone and Thyroid Dysfunction

Amiodarone is a medication used to treat heart rhythm disorders. However, around 1 in 6 patients taking amiodarone develop thyroid dysfunction. This can manifest as either amiodarone-induced hypothyroidism (AIH) or amiodarone-induced thyrotoxicosis (AIT).

The pathophysiology of AIH is thought to be due to the high iodine content of amiodarone causing a Wolff-Chaikoff effect. This is an autoregulatory phenomenon where thyroxine formation is inhibited due to high levels of circulating iodide. Despite this, amiodarone may be continued if desirable.

On the other hand, AIT may be divided into two types: type 1 and type 2. Type 1 is caused by excess iodine-induced thyroid hormone synthesis, while type 2 is caused by amiodarone-related destructive thyroiditis. In patients with AIT, amiodarone should be stopped if possible.

It is important for healthcare professionals to monitor patients taking amiodarone for any signs of thyroid dysfunction and adjust treatment accordingly.

Chlordiazepoxide or diazepam are administered to manage delirium tremens/alcohol withdrawal.

When a patient experiences delirium tremens due to alcohol withdrawal after dependency, chlordiazepoxide or diazepam are commonly prescribed. This condition often leads to the manifestation of visual and auditory hallucinations. While haloperidol can be beneficial in calming the patient, the primary treatment for delirium tremens is administering 10-30 mg of chlordiazepoxide four times daily.

Alcohol withdrawal occurs when an individual who has been consuming alcohol chronically suddenly stops or reduces their intake. Chronic alcohol consumption enhances the inhibitory effects of GABA in the central nervous system, similar to benzodiazepines, and inhibits NMDA-type glutamate receptors. However, alcohol withdrawal leads to the opposite effect, resulting in decreased inhibitory GABA and increased NMDA glutamate transmission. Symptoms of alcohol withdrawal typically start at 6-12 hours and include tremors, sweating, tachycardia, and anxiety. Seizures are most likely to occur at 36 hours, while delirium tremens, which includes coarse tremors, confusion, delusions, auditory and visual hallucinations, fever, and tachycardia, peak at 48-72 hours.

Patients with a history of complex withdrawals from alcohol, such as delirium tremens, seizures, or blackouts, should be admitted to the hospital for monitoring until their withdrawals stabilize. The first-line treatment for alcohol withdrawal is long-acting benzodiazepines, such as chlordiazepoxide or diazepam, which are typically given as part of a reducing dose protocol. Lorazepam may be preferable in patients with hepatic failure. Carbamazepine is also effective in treating alcohol withdrawal, while phenytoin is said to be less effective in treating alcohol withdrawal seizures.

Grief is a natural response to the death of a loved one and does not always require medical intervention. However, understanding the potential stages of grief can help determine if a patient is experiencing a normal reaction or a more significant problem. The most common model of grief divides it into five stages: denial, anger, bargaining, depression, and acceptance. It is important to note that not all patients will experience all five stages. Atypical grief reactions are more likely to occur in women, sudden and unexpected deaths, problematic relationships before death, and lack of social support. Delayed grief, which occurs when grieving does not begin for more than two weeks, and prolonged grief, which is difficult to define but may last beyond 12 months, are features of atypical grief reactions.

To calculate the amount of Hartmann’s solution to be administered in the first 24 hours after a burn, multiply the body surface area by the weight in kilograms. For example, if the body surface area is 4 and the weight is 70 kg, the calculation would be 4 x 25 x 70 = 7000 ml. Half of this amount should be given within the first 8 hours after the burn, which equals 3.5 liters.

Fluid Resuscitation for Burns

Fluid resuscitation is necessary for patients with burns that cover more than 15% of their total body area (10% for children). The primary goal of resuscitation is to prevent the burn from deepening. Most fluid is lost within the first 24 hours after injury, and during the first 8-12 hours, fluid shifts from the intravascular to the interstitial fluid compartments, which can compromise circulatory volume. However, fluid resuscitation causes more fluid to enter the interstitial compartment, especially colloid, which should be avoided in the first 8-24 hours. Protein loss also occurs.

The Parkland formula is used to calculate the total fluid requirement in 24 hours, which is given as 4 ml x (total burn surface area (%)) x (body weight (kg)). Fifty percent of the total fluid requirement is given in the first 8 hours, and the remaining 50% is given in the next 16 hours. The resuscitation endpoint is a urine output of 0.5-1.0 ml/kg/hour in adults, and the rate of fluid is increased to achieve this.

It is important to note that the starting point of resuscitation is the time of injury, and fluids already given should be deducted. After 24 hours, colloid infusion is begun at a rate of 0.5 ml x (total burn surface area (%)) x (body weight (kg)), and maintenance crystalloid (usually dextrose-saline) is continued at a rate of 1.5 ml x (burn area) x (body weight). Colloids used include albumin and FFP, and antioxidants such as vitamin C can be used to minimize oxidant-mediated contributions to the inflammatory cascade in burns. High tension electrical injuries and inhalation injuries require more fluid, and monitoring of packed cell volume, plasma sodium, base excess, and lactate is essential.

For a child between 3 and 4 years old, the recommended immunisations are the MMR vaccine and the 4-in-1 booster, which includes vaccinations for diphtheria, tetanus, whooping cough, and polio. It is important to note that the child should have already received a BCG vaccination when they were between 0 and 12 months old if their parents were born in a country with a high incidence of tuberculosis. The HPV vaccine is not recommended for children of this age. The 3-in-1 booster and meningococcal B vaccine is an inappropriate combination, as is the 6-in-1 vaccine and meningococcal ACWY vaccine.

The UK immunisation schedule recommends certain vaccines at different ages. At birth, the BCG vaccine is given if the baby is at risk of tuberculosis. At 2, 3, and 4 months, the ‘6-1 vaccine’ (diphtheria, tetanus, whooping cough, polio, Hib and hepatitis B) and oral rotavirus vaccine are given, along with Men B and PCV at certain intervals. At 12-13 months, the Hib/Men C, MMR, and PCV vaccines are given, along with Men B. At 3-4 years, the ‘4-in-1 preschool booster’ (diphtheria, tetanus, whooping cough and polio) and MMR vaccines are given. At 12-13 years, the HPV vaccination is given, and at 13-18 years, the ‘3-in-1 teenage booster’ (tetanus, diphtheria and polio) and Men ACWY vaccines are given. Additionally, the flu vaccine is recommended annually for children aged 2-8 years.

It is important to note that the meningitis ACWY vaccine has replaced meningitis C for 13-18 year-olds due to an increased incidence of meningitis W disease in recent years. The ACWY vaccine will also be offered to new students (up to the age of 25 years) at university. GP practices will automatically send letters inviting 17-and 18-year-olds in school year 13 to have the Men ACWY vaccine. Students going to university or college for the first time as freshers, including overseas and mature students up to the age of 25, should contact their GP to have the Men ACWY vaccine, ideally before the start of the academic year.

It is worth noting that the Men C vaccine used to be given at 3 months but has now been discontinued. This is because the success of the Men C vaccination programme means there are almost no cases of Men C disease in babies or young children in the UK any longer. All children will continue to be offered the Hib/Men C vaccine at one year of age, and the Men ACWY vaccine at 14 years of age to provide protection across all age groups.

Treatment options for massive haemoptysis in cystic fibrosis patients

Massive haemoptysis in cystic fibrosis (CF) patients can be a life-threatening complication. Non-invasive ventilation is not recommended as it may increase the risk of aspiration of blood and disturb clot formation. IV antibiotics should be given to treat acute inflammation related to pulmonary infection. Tranexamic acid, an anti-fibrinolytic drug, can be given orally or intravenously up to four times per day until bleeding is controlled. CF patients have impaired absorption of fat-soluble vitamins, including vitamin K, which may lead to prolonged prothrombin time. In such cases, IV vitamin K should be given. Bronchial artery embolisation is often required to treat massive haemoptysis, particularly when larger hypertrophied bronchial arteries are seen on CT. This procedure is performed by an interventional vascular radiologist and may be done under sedation or general anaesthetic if the patient is in extremis.

Pregnant women should avoid taking ACE inhibitors like ramipril as they can lead to fetal abnormalities and renal failure. These medications are believed to hinder the production of fetal urine, resulting in oligohydramnios, and increase the likelihood of cranial and cardiac defects. However, other drugs do not pose any known risks during pregnancy and can be continued if necessary.

Angiotensin-converting enzyme (ACE) inhibitors are commonly used as the first-line treatment for hypertension and heart failure in younger patients. However, they may not be as effective in treating hypertensive Afro-Caribbean patients. These inhibitors are also used to treat diabetic nephropathy and for secondary prevention of ischaemic heart disease. The mechanism of action of ACE inhibitors is to inhibit the conversion of angiotensin I to angiotensin II. They are metabolized in the liver through phase 1 metabolism.

ACE inhibitors may cause side effects such as cough, which occurs in around 15% of patients and may occur up to a year after starting treatment. This is thought to be due to increased bradykinin levels. Angioedema may also occur up to a year after starting treatment. Hyperkalaemia and first-dose hypotension are other potential side effects, especially in patients taking diuretics. ACE inhibitors should be avoided during pregnancy and breastfeeding, and caution should be exercised in patients with renovascular disease, aortic stenosis, or hereditary or idiopathic angioedema.

Patients receiving high-dose diuretic therapy (more than 80 mg of furosemide a day) are at an increased risk of hypotension when taking ACE inhibitors. Before initiating treatment, urea and electrolytes should be checked, and after increasing the dose, a rise in creatinine and potassium may be expected. Acceptable changes include an increase in serum creatinine up to 30% from baseline and an increase in potassium up to 5.5 mmol/l. Patients with undiagnosed bilateral renal artery stenosis may experience significant renal impairment. The current NICE guidelines provide a flow chart for the management of hypertension.

Understanding Neuroleptic Malignant Syndrome: Symptoms, Treatment, and Prognosis

Neuroleptic Malignant Syndrome (NMS) is a rare but life-threatening reaction to neuroleptic medication. It can occur either on initiation of therapy or after a dose increase and is associated with all known neuroleptic drugs. Symptoms include muscular rigidity, hyperthermia, change in consciousness, delirium, and autonomic instability. The pathophysiology of NMS is not entirely understood, but it is thought to be secondary to dopamine D2 receptor antagonism.

Prognosis is best when the syndrome is identified and treated early. Treatment involves discontinuing all neuroleptic medications, and symptoms tend to settle within 1-2 weeks. The risk of recurrence may be reduced by switching to an atypical, rather than a high-potency, antipsychotic. Sometimes these patients will be managed in the Intensive Care Unit depending on the severity of their symptoms.

Contrary to popular belief, NMS has been associated with all known neuroleptic drugs, including clozapine. Reintroduction of the drug that caused NMS increases the risk of mortality. The use of high-potency neuroleptics like haloperidol has been associated with a mildly increased risk.

In addition to withdrawal of the afflicting medication, adjunctive medications can be given such as muscle relaxants like lorazepam and bromocriptine, however, evidence for these is limited. Most patients will be significantly dehydrated and will have rhabdomyolysis, therefore fluids should be given to prevent renal failure.

In conclusion, understanding the symptoms, treatment, and prognosis of NMS is crucial for healthcare professionals who prescribe neuroleptic medication. Early identification and prompt treatment can improve outcomes for patients.